CO2019012756A2 - Anticuerpos agonistas contra btla y sus usos - Google Patents

Anticuerpos agonistas contra btla y sus usos

Info

Publication number
CO2019012756A2
CO2019012756A2 CONC2019/0012756A CO2019012756A CO2019012756A2 CO 2019012756 A2 CO2019012756 A2 CO 2019012756A2 CO 2019012756 A CO2019012756 A CO 2019012756A CO 2019012756 A2 CO2019012756 A2 CO 2019012756A2
Authority
CO
Colombia
Prior art keywords
antibodies against
agonist antibodies
btla
against btla
antibodies
Prior art date
Application number
CONC2019/0012756A
Other languages
English (en)
Inventor
Shane Krummen Atwell
Victor H Obungu
Andrew Charles Vendel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2019012756A2 publication Critical patent/CO2019012756A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan anticuerpos que se fijan a BTLA, y métodos para usarlos, en donde dichos anticuerpos son útiles como agentes para tratar afecciones asociadas a la enfermedad autoinmunitaria, que incluyen el tratamiento de lupus.
CONC2019/0012756A 2017-05-19 2019-11-15 Anticuerpos agonistas contra btla y sus usos CO2019012756A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19
PCT/US2018/032218 WO2018213113A1 (en) 2017-05-19 2018-05-11 Btla agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CO2019012756A2 true CO2019012756A2 (es) 2020-01-17

Family

ID=62245543

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0012756A CO2019012756A2 (es) 2017-05-19 2019-11-15 Anticuerpos agonistas contra btla y sus usos

Country Status (25)

Country Link
US (2) US10604573B2 (es)
EP (1) EP3625257A1 (es)
JP (2) JP6790304B2 (es)
KR (3) KR102294051B1 (es)
CN (3) CN117402245A (es)
AR (1) AR111752A1 (es)
AU (2) AU2018269585B2 (es)
BR (1) BR112019021547A2 (es)
CA (2) CA3064518A1 (es)
CL (1) CL2019003215A1 (es)
CO (1) CO2019012756A2 (es)
CR (1) CR20190521A (es)
DO (1) DOP2019000293A (es)
EA (1) EA201992460A1 (es)
EC (1) ECSP19082184A (es)
JO (1) JOP20190261A1 (es)
MA (1) MA49133A (es)
MX (1) MX2019013604A (es)
MY (1) MY197425A (es)
NZ (1) NZ758360A (es)
PE (1) PE20191843A1 (es)
PH (1) PH12019502575A1 (es)
TW (4) TWI804044B (es)
WO (1) WO2018213113A1 (es)
ZA (1) ZA201906954B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
US20230391872A1 (en) * 2020-10-23 2023-12-07 Anaptysbio, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
WO2023143565A1 (en) * 2022-01-29 2023-08-03 Hifibio (Hk) Limited Anti-btla antibodies and uses thereof in treating cancer
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
WO2004039394A1 (en) * 2002-10-25 2004-05-13 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
AU2007334264A1 (en) * 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to BTLA and methods of use
AU2010276580A1 (en) * 2009-07-31 2012-03-15 Medarex, L.L.C. Fully human antibodies to BTLA
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
WO2014183885A1 (en) * 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
WO2016176583A1 (en) * 2015-04-29 2016-11-03 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体

Also Published As

Publication number Publication date
EA201992460A1 (ru) 2020-03-18
PH12019502575A1 (en) 2020-07-13
TWI804044B (zh) 2023-06-01
US10604573B2 (en) 2020-03-31
AR111752A1 (es) 2019-08-14
US20200239578A1 (en) 2020-07-30
CL2019003215A1 (es) 2020-04-13
AU2018269585B2 (en) 2021-09-02
KR102294051B1 (ko) 2021-08-27
KR20190140969A (ko) 2019-12-20
CR20190521A (es) 2020-01-06
JP2020518288A (ja) 2020-06-25
PE20191843A1 (es) 2019-12-31
DOP2019000293A (es) 2019-12-15
CN110621699B (zh) 2023-10-31
CN110621699A (zh) 2019-12-27
TWI677504B (zh) 2019-11-21
KR20220158847A (ko) 2022-12-01
WO2018213113A1 (en) 2018-11-22
US11396545B2 (en) 2022-07-26
MX2019013604A (es) 2019-12-18
CN117402244A (zh) 2024-01-16
EP3625257A1 (en) 2020-03-25
MA49133A (fr) 2020-03-25
AU2018269585A1 (en) 2019-10-31
JOP20190261A1 (ar) 2019-11-05
NZ758360A (en) 2022-10-28
ECSP19082184A (es) 2019-11-30
AU2021277743A1 (en) 2021-12-23
TW201904991A (zh) 2019-02-01
CA3064518A1 (en) 2018-11-22
CA3184628A1 (en) 2018-11-22
TW202334237A (zh) 2023-09-01
JP7072622B2 (ja) 2022-05-20
TW201946932A (zh) 2019-12-16
MY197425A (en) 2023-06-16
TW202233681A (zh) 2022-09-01
KR20210106033A (ko) 2021-08-27
JP6790304B2 (ja) 2020-11-25
BR112019021547A2 (pt) 2020-05-12
TWI747043B (zh) 2021-11-21
ZA201906954B (en) 2021-06-30
US20180334502A1 (en) 2018-11-22
JP2021019642A (ja) 2021-02-18
CN117402245A (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
CO2019012756A2 (es) Anticuerpos agonistas contra btla y sus usos
CO2017002719A2 (es) Anticuerpos anti-glucagón
CL2017003404A1 (es) Compuestos antibacterianos
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
ECSP17070399A (es) Anticuerpos contra icos
UY35417A (es) Anticuerpos dirigidos contra il-33 y sus usos.
CR20190179A (es) Anticuerpos anti-il-33 y usos de estos
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
NI201700060A (es) Agonistas parciales del receptor de insulina
DOP2017000083A (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
PE20171556A1 (es) Agentes de union a cd123 y usos de estos
CL2019002792A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando el mismo.
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
NI201800134A (es) Anticuerpos antifactor de la coagulación xi
BR112017006520A2 (pt) métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28
UY35327A (es) ?4,5-dihidro-1,2,4-oxadiazoles disustituidos en 3,5 y composiciones y métodos para controlar plagas de nematodos?.
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
AR106133A1 (es) Métodos para el tratamiento de la epilepsia
CL2019002802A1 (es) Anticuerpos biespecíficos anti-pd-l1-anti-tim-3.
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
DOP2019000082A (es) Anticuerpos anti-il-33 y usos de los mismos
ECSP17039183A (es) Agonistas parciales del receptor de insulina
AR103227A1 (es) Anticuerpos anti-csf1r para el tratamiento de svp
AR098780A1 (es) Proceso de obtención de micropartículas de quitosano